Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6071537 | VIVUS | Anticonvulsant derivatives useful in treating obesity |
Jun, 2017
(6 years ago) | |
US7056890 | VIVUS | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(3 years ago) | |
US7659256 | VIVUS | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(3 years ago) | |
US7553818 | VIVUS | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(3 years ago) | |
US7674776 | VIVUS | Combination therapy for effecting weight loss and treating obesity |
Jun, 2020
(3 years ago) | |
US8895057 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(4 years from now) | |
US9011906 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(4 years from now) | |
US8895058 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(4 years from now) | |
US9011905 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(4 years from now) | |
US8580298 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
May, 2029
(5 years from now) | |
US8580299 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Jun 24, 2025 |
New Combination(NC) | Jul 17, 2015 |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient
Market Authorisation Date: 17 July, 2012
Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight; For chronic weight management in ad...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL